• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖原贮积病 I 型与骨骼:临床与细胞特征。

Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization.

机构信息

Bone Metabolism Diseases and Diabetes Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Endocrinology Unit, Niguarda Hospital, Milan, Italy.

出版信息

Calcif Tissue Int. 2024 Nov;115(5):661-672. doi: 10.1007/s00223-024-01302-4. Epub 2024 Oct 25.

DOI:10.1007/s00223-024-01302-4
PMID:39453459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11531425/
Abstract

Glycogen storage disease (GSD) is the most prevalent inherited disorder of glycogen metabolism for which no causal treatment is available. In recent years, thanks to the improved clinical management, the life expectancy of these patients extended, disclosing previously unidentified adverse conditions in other organs. In this study, we evaluated the clinical bone complications and the cellular responses in 20 patients (aged 14.1 ± 3.4 years) affected by GSD type I. Fragility fractures were reported in 35% of the patients, which were older than unfractured patients. They involved appendicular skeletal segments, while no vertebral deformity was detected. 60% of the patients had a bone mineral density (BMD) "below the expected range for age", and lumbar spine (LS) BMD Z-scores positively correlated with muscle strength. Circulating mineral and bone markers showed reduction in the older subjects, with no increase in the pubertal age. Significant correlations could not be detected between circulating markers and LS BMD Z-scores, except for sclerostin levels, which also correlated with muscle strength. The osteoclasts differentiated from patients' peripheral blood mononuclear cells did not show cell-autonomous alterations. However, circulating osteoclast precursors from healthy individuals cultured in the presence of patients' sera exhibited increased osteoclastogenesis compared to control sera suggesting that GSD type I serum factors could affect osteoclast function in a non-autonomous manner. In contrast, circulating osteoprogenitors were unremarkable.

摘要

糖原贮积病(GSD)是最常见的糖原代谢遗传性疾病,目前尚无病因治疗方法。近年来,由于临床管理水平的提高,这些患者的预期寿命延长,从而揭示了其他器官以前未识别的不良情况。在这项研究中,我们评估了 20 例 I 型 GSD 患者(年龄 14.1±3.4 岁)的临床骨骼并发症和细胞反应。35%的患者报告有脆性骨折,且骨折患者年龄大于未骨折患者。骨折发生于四肢骨骼部位,而未发现椎体畸形。60%的患者骨密度(BMD)“低于年龄预期范围”,腰椎(LS)BMD Z 评分与肌肉力量呈正相关。循环矿物质和骨标志物在年龄较大的患者中减少,但在青春期年龄没有增加。除了骨硬化蛋白水平与肌肉力量呈正相关外,循环标志物与 LS BMD Z 评分之间未检测到显著相关性。来自患者外周血单核细胞的破骨细胞分化未显示细胞自主性改变。然而,来自健康个体的循环破骨细胞前体在患者血清存在的情况下培养时,破骨细胞生成增加,与对照血清相比,这表明 I 型 GSD 血清因子可能以非自主性方式影响破骨细胞功能。相比之下,循环成骨细胞前体无明显变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/f95a0e381ff1/223_2024_1302_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/5461e082e476/223_2024_1302_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/75855094d352/223_2024_1302_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/df683d17ca2b/223_2024_1302_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/0e861b166b16/223_2024_1302_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/42541cf99481/223_2024_1302_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/f95a0e381ff1/223_2024_1302_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/5461e082e476/223_2024_1302_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/75855094d352/223_2024_1302_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/df683d17ca2b/223_2024_1302_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/0e861b166b16/223_2024_1302_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/42541cf99481/223_2024_1302_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11531425/f95a0e381ff1/223_2024_1302_Fig6_HTML.jpg

相似文献

1
Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization.糖原贮积病 I 型与骨骼:临床与细胞特征。
Calcif Tissue Int. 2024 Nov;115(5):661-672. doi: 10.1007/s00223-024-01302-4. Epub 2024 Oct 25.
2
Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX.I型、III型和IX型糖原贮积病患者的骨矿物质密度和骨转换标志物
J Inherit Metab Dis. 2004;27(1):1-9. doi: 10.1023/B:BOLI.0000016632.13234.56.
3
Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study.Ia型糖原贮积病儿童、青少年及成人的骨矿物质密度:一项横断面和纵向研究
J Inherit Metab Dis. 2003;26(4):371-84. doi: 10.1023/a:1025111220095.
4
Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit.III型糖原贮积病患者骨矿物质密度降低可能是由于肌肉和骨骼的综合缺乏所致。
J Inherit Metab Dis. 2008 Jun;31(3):418-23. doi: 10.1007/s10545-008-0830-0. Epub 2008 Apr 4.
5
Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria.尿黑酸症中破骨细胞生成增强的机制。
Am J Pathol. 2018 Apr;188(4):1059-1068. doi: 10.1016/j.ajpath.2017.12.008. Epub 2018 Jan 17.
6
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.杜氏肌营养不良症的骨骼健康:临床和生化相关性。
J Endocrinol Invest. 2022 Mar;45(3):517-525. doi: 10.1007/s40618-021-01676-4. Epub 2021 Sep 15.
7
Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis.III型糖原贮积病患者骨矿物质密度降低:代谢失衡与骨稳态之间可能存在关联的证据。
Bone. 2016 May;86:79-85. doi: 10.1016/j.bone.2016.02.012. Epub 2016 Feb 23.
8
Low bone mass in glycogen storage disease type 1 is associated with reduced muscle force and poor metabolic control.1型糖原贮积病患者的低骨量与肌肉力量降低和代谢控制不佳有关。
J Pediatr. 2002 Sep;141(3):350-6. doi: 10.1067/mpd.2002.126456.
9
Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy.中重度脑瘫患儿及青少年的骨密度与骨代谢
Pediatrics. 2002 Jul;110(1 Pt 1):e5. doi: 10.1542/peds.110.1.e5.
10
Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.苯丙酮尿症患者的骨损伤特征是循环破骨细胞前体和活化 T 细胞增加。
PLoS One. 2010 Nov 30;5(11):e14167. doi: 10.1371/journal.pone.0014167.

本文引用的文献

1
TBS correlates with bone density and microstructure at trabecular and cortical bone evaluated by HR-pQCT.TBS 与 HR-pQCT 评估的骨小梁和皮质骨的骨密度和微观结构相关。
J Bone Miner Metab. 2024 May;42(3):352-360. doi: 10.1007/s00774-024-01508-4. Epub 2024 Apr 25.
2
The relationship between bone strain index, bone mass, microarchitecture and mechanical behavior in human vertebrae: an ex vivo study.人体椎骨中骨应变指数、骨量、微结构和力学性能的关系:一项离体研究。
Osteoporos Int. 2024 Jun;35(6):1069-1075. doi: 10.1007/s00198-024-07066-9. Epub 2024 Mar 23.
3
Bone health status evaluation in men by means of REMS technology.
男性的骨骼健康状况评估采用 REMS 技术。
Aging Clin Exp Res. 2024 Mar 18;36(1):74. doi: 10.1007/s40520-024-02728-4.
4
Muscle strength deficits are associated with low bone mineral density in young pediatric cancer survivors: The iBoneFIT project.肌肉力量缺陷与年轻儿科癌症幸存者的低骨密度有关:iBoneFIT 项目。
J Sport Health Sci. 2024 May;13(3):419-427. doi: 10.1016/j.jshs.2024.01.003. Epub 2024 Jan 12.
5
Glycogen storage diseases.糖原贮积病。
Nat Rev Dis Primers. 2023 Sep 7;9(1):46. doi: 10.1038/s41572-023-00456-z.
6
Sclerostin: clinical insights in muscle-bone crosstalk.骨硬化蛋白:肌肉-骨骼相互作用的临床新视角。
J Int Med Res. 2023 Aug;51(8):3000605231193293. doi: 10.1177/03000605231193293.
7
Glycogen storage diseases: An update.糖原贮积病:更新。
World J Gastroenterol. 2023 Jul 7;29(25):3932-3963. doi: 10.3748/wjg.v29.i25.3932.
8
The Liver and Glycogen: In Sickness and in Health.肝脏与糖原:病与健康。
Int J Mol Sci. 2023 Mar 24;24(7):6133. doi: 10.3390/ijms24076133.
9
Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs.糖原贮积病 Ia 型:当前的管理选择、负担和未满足的需求。
Nutrients. 2021 Oct 27;13(11):3828. doi: 10.3390/nu13113828.
10
Bone Mineral Density in Patients with Hepatic Glycogen Storage Diseases.肝糖原贮积病患者的骨密度。
Nutrients. 2021 Aug 27;13(9):2987. doi: 10.3390/nu13092987.